Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Small but not minor

Cyclacel Pharmaceuticals Inc. believes its decision to acquire Align Pharmaceuticals LLC ultimately will expand its options and give it greater leverage when it comes time to partner its cancer compounds - even though the acquisition is so small it's almost below the radar.

Align (Cary, N.C.) is a three-person company that markets three drugs used as adjuncts in cancer treatment. Xclair Cream is indicated for the management of dermatitis caused by radiation therapy. Numoisyn Liquid and Numoisyn Lozenges are indicated for the management of xerostomia from cancer therapy

Read the full 874 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers